Literature DB >> 9138698

Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type.

M G Belvisi1, M A Saunders, S J Hirst, M H Yacoub, P J Barnes, J A Mitchell.   

Abstract

1. Cyclo-oxygenase (COX) is the enzyme that converts arachidonic acid to prostaglandin H2 (PGH2) which can then be further metabolized to prostanoids which modulate various airway functions. COX exists in at least two isoforms. COX-1 is expressed constitutively, whereas COX-2 is expressed in response to pro-inflammatory stimuli. Prostanoids are produced under physiological and pathophysiological conditions by many cell types in the lung. However, the regulation of the different COX isoforms in human airway smooth muscle (HASM) cells has not yet been determined. 2. COX-1 and COX-2 protein were measured by Western blot analysis with specific antibodies for COX-1 and COX-2. COX-2 mRNA levels were assessed by Northern blot analysis by use of a COX-2 cDNA probe. COX activity was determined by measuring conversion of either endogenous or exogenous arachidonic acid to three metabolites, PGE2, thromboxane B2 or 6-ketoPGF1 alpha by radioimmunoassay. 3. Under control culture conditions HASM cells expressed COX-1, but not COX-2, protein. However, a mixture of cytokines (interleukin-1 beta (IL-1 beta), tumour necrosis factor alpha (TNF alpha) and interferon gamma (IFN gamma) each at 10 ng ml-1) induced COX-2 mRNA expression, which was maximal at 12 h and inhibited by dexamethasone (1 microM; added 30 min before the cytokines). Furthermore, COX-2 protein was detected 24 h after the cytokine treatment and the expression of this protein was also inhibited by dexamethasone (1 microM) and cyclohexamide (10 micrograms ml-1; added 30 min before the cytokines). 4. Untreated HASM cells released low or undetectable amounts of all COX metabolites measured over a 24 h period. Incubation of the cells with the cytokine mixture (IL-1 beta, TNF alpha, IFN gamma each at 10 ng ml-1 for 24 h) caused the accumulation of PGE2 and 6-keto-PGF1 alpha. 5. In experiments where COX-2 metabolized endogenous stores of arachidonic acid, treatment of HASM cells with IL-1 beta in combination with TNF alpha caused a similar release of PGE2 to that when the three cytokines were given in combination. 6. In other experiments designed to measure COX-2 activity directly, cells were treated with cytokines for 24 h before fresh culture medium was added containing exogenous arachidonic acid (30 microM for 15 min) after which PGE2 was measured. IL-1 beta and TNF alpha increased COX-2 activity and an additional small increase was produced by the three cytokines in combination. 7. These findings suggest that the increased expression of COX-2 is intimately involved in the exaggerated release of prostanoids from HASM cells exposed to pro-inflammatory cytokines. These data indicate a role for airway smooth muscle cells, in addition to their contractile function, as inflammatory cells involved in the production of mediators which may contribute to the inflammatory response seen in diseases such as asthma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138698      PMCID: PMC1564529          DOI: 10.1038/sj.bjp.0700963

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Induction of eotaxin expression and release from human airway smooth muscle cells by IL-1beta and TNFalpha: effects of IL-10 and corticosteroids.

Authors:  K F Chung; H J Patel; E J Fadlon; J Rousell; E B Haddad; P J Jose; J Mitchell; M Belvisi
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells.

Authors:  M P Hallsworth; C H Twort; T H Lee; S J Hirst
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

Review 3.  Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1.

Authors:  Nicolas G Bazan; Jorgelina M Calandria; Charles N Serhan
Journal:  J Lipid Res       Date:  2010-04-09       Impact factor: 5.922

4.  Interleukin-1alpha and tumour necrosis factor-alpha modulate airway smooth muscle DNA synthesis by induction of cyclo-oxygenase-2: inhibition by dexamethasone and fluticasone propionate.

Authors:  R Vlahos; A G Stewart
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

5.  Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells.

Authors:  Pamela L Rice; Bradley S Barrett; Jason M Fritz; Mary C Srebernak; Lori R Kisley; Alvin M Malkinson; Lori D Dwyer-Nield
Journal:  Exp Lung Res       Date:  2010-11       Impact factor: 2.459

6.  Cyclooxygenase-2 and microRNA-155 expression are elevated in asthmatic airway smooth muscle cells.

Authors:  Brian S Comer; Blanca Camoretti-Mercado; Paul C Kogut; Andrew J Halayko; Julian Solway; William T Gerthoffer
Journal:  Am J Respir Cell Mol Biol       Date:  2015-04       Impact factor: 6.914

Review 7.  Aspirin-induced asthma: clinical aspects, pathogenesis and management.

Authors:  Ahmed M Hamad; Amy M Sutcliffe; Alan J Knox
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Ozone modulates IL-6 secretion in human airway epithelial and smooth muscle cells.

Authors:  Gautam Damera; Hengjiang Zhao; Miao Wang; Michael Smith; Christopher Kirby; William F Jester; John A Lawson; Reynold A Panettieri
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-06       Impact factor: 5.464

9.  Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells.

Authors:  Ute Oltmanns; Razao Issa; Maria B Sukkar; Matthias John; K Fan Chung
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

10.  Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El-Bassiouny; Mona M K Zoheiry; Mona M F Nosseir; Eman G El-Ahwany; Raafat A Ibrahim; Nora E I El-Bassiouni
Journal:  MedGenMed       Date:  2007-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.